Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115436) titled 'A Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and QT Interval Effects of a Single Dose of YZJ-4729 Tartrate Injection' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Third Xiangya Hospital, Central South University
Condition:
Pain
Intervention:
Group 1:3.5mg (including 3 placebo cases):On the day of administration, a single intravenous dose of YZJ-4729 Tartrate Injection (3.5 mg) or placebo was given under fasting conditions, with an infusion duration of 10 minutes (± 1 minute).No water intake was allowed from 2 hours before adm...